Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic side population adipose-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
An investigational allogeneic cell therapy consisting of side population adipose-derived mesenchymal stem cells (SPADMSCs) obtained from volunteer donors. Developed by the Tehran University of Medical Sciences, this therapy is being evaluated for the treatment of spinal muscular atrophy type 1 (SMA type 1), also known as Werdnig-Hoffman disease. SMA type 1 is a severe autosomal recessive neurodegenerative disorder caused by mutations in the SMN1 gene, leading to the loss of alpha motor neurons in the spinal cord. The therapy is administered via intrathecal injection, where the stem cells are hypothesized to provide neurotrophic support and paracrine signaling to protect degenerating motor neurons, potentially slowing disease progression and improving motor function in affected infants.
- Other names
- SPADMSCsallogeneic adipose-derived mesenchymal stem cellsADMSCsadipose derived mesenchymal stem cell-Tehran University of Medical Sciences-spinal muscular atrophy type 1
Beyond the preview
Go deeper on allogeneic side population adipose-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic side population adipose-derived mesenchymal stem cells.